Last reviewed · How we verify
Arterolane-piperaquine
Arterolane-piperaquine is a fixed-dose combination antimalarial that works by inhibiting parasite protein synthesis and disrupting the parasite's mitochondrial function.
Arterolane-piperaquine is a fixed-dose combination antimalarial that works by inhibiting parasite protein synthesis and disrupting the parasite's mitochondrial function. Used for Uncomplicated malaria caused by Plasmodium falciparum, Uncomplicated malaria caused by Plasmodium vivax.
At a glance
| Generic name | Arterolane-piperaquine |
|---|---|
| Sponsor | University of Oxford |
| Drug class | Artemisinin-based combination therapy (ACT) |
| Target | Malaria parasite (Plasmodium falciparum and P. vivax) protein synthesis and heme detoxification pathway |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | Phase 3 |
Mechanism of action
Arterolane is a semi-synthetic artemisinin derivative that rapidly kills malaria parasites by generating reactive oxygen species and damaging parasite proteins. Piperaquine is a bisquinoline that accumulates in the parasite's food vacuole and inhibits heme detoxification, leading to parasite death. Together, they provide rapid parasite clearance and extended post-treatment suppression.
Approved indications
- Uncomplicated malaria caused by Plasmodium falciparum
- Uncomplicated malaria caused by Plasmodium vivax
Common side effects
- Headache
- Fever
- Nausea
- Vomiting
- Abdominal pain
Key clinical trials
- Comparison of Arterolane-piperaquine Versus Arterolane-piperaquine+Mefloquine Versus Artemether-lumefantrine in Kenyan Children (PHASE3)
- Arterolane-PQP Versus DHA-PQP in Uncomplicated Falciparum Malaria in Eastern Myanmar (PHASE2, PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |